Xlife Sciences AG
SIX:XLS

Watchlist Manager
Xlife Sciences AG Logo
Xlife Sciences AG
SIX:XLS
Watchlist
Price: 29.1 CHF 0.69% Market Closed
Market Cap: 167.1m CHF
Have any thoughts about
Xlife Sciences AG?
Write Note

Xlife Sciences AG
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Xlife Sciences AG
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Xlife Sciences AG
SIX:XLS
Capital Expenditures
-CHf41.1k
CAGR 3-Years
43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Capital Expenditures
-CHf292.6m
CAGR 3-Years
-47%
CAGR 5-Years
-56%
CAGR 10-Years
-40%
Siegfried Holding AG
SIX:SFZN
Capital Expenditures
-CHf139.1m
CAGR 3-Years
-11%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Capital Expenditures
-CHf1.6B
CAGR 3-Years
-13%
CAGR 5-Years
-19%
CAGR 10-Years
-23%
Tecan Group AG
SIX:TECN
Capital Expenditures
-CHf28.9m
CAGR 3-Years
12%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Capital Expenditures
-CHf35.3m
CAGR 3-Years
-34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Xlife Sciences AG
Glance View

Market Cap
166m CHF
Industry
Life Sciences Tools & Services

Xlife Sciences AG focuses on the value development of performance promising technologies in life sciences. The company is headquartered in Zurich, Zuerich and currently employs 19 full-time employees. The company went IPO on 2019-09-30. The firm focuses on investing in technologies in the life science industry. The company supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The firm offers its investors direct access to the further development of technologies at a very early stage. The firm cooperates with industrial partners and universities.

XLS Intrinsic Value
1.37 CHF
Overvaluation 95%
Intrinsic Value
Price

See Also

What is Xlife Sciences AG's Capital Expenditures?
Capital Expenditures
-41.1k CHF

Based on the financial report for Dec 31, 2023, Xlife Sciences AG's Capital Expenditures amounts to -41.1k CHF.

What is Xlife Sciences AG's Capital Expenditures growth rate?
Capital Expenditures CAGR 3Y
43%

Over the last year, the Capital Expenditures growth was 49%. The average annual Capital Expenditures growth rates for Xlife Sciences AG have been 43% over the past three years .

Back to Top